2021
Tumor Characteristic Variations between Symptomatic and Asymptomatic Endometrial Cancer
VINKLEROVÁ, Petra, Markéta BEDNAŘÍKOVÁ, Luboš MINÁŘ, Michal FELSINGER, Jitka HAUSNEROVÁ et. al.Základní údaje
Originální název
Tumor Characteristic Variations between Symptomatic and Asymptomatic Endometrial Cancer
Autoři
VINKLEROVÁ, Petra (203 Česká republika, domácí), Markéta BEDNAŘÍKOVÁ (203 Česká republika, domácí), Luboš MINÁŘ (203 Česká republika, domácí), Michal FELSINGER (203 Česká republika, domácí), Jitka HAUSNEROVÁ (203 Česká republika, domácí), Petra OVESNÁ (203 Česká republika, domácí) a Vít WEINBERGER (203 Česká republika, garant, domácí)
Vydání
Healthcare, Basel, MDPI, 2021, 2227-9032
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30214 Obstetrics and gynaecology
Stát vydavatele
Švýcarsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 3.160
Kód RIV
RIV/00216224:14110/21:00122021
Organizační jednotka
Lékařská fakulta
UT WoS
000677363300001
Klíčová slova anglicky
endometrial cancer; tumor markers; ER; PR; p53; L1CAM
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 24. 8. 2021 10:11, Mgr. Tereza Miškechová
Anotace
V originále
Endometrial cancer is the most common gynecologic malignancy in Europe and usually diagnosed in its initial stage owing to early symptoms of abnormal bleeding. There is no population screening for this disease, although it can sometimes be accidentally diagnosed in asymptomatic patients. Our study aims to determine differences in clinical and tumor characteristics between an asymptomatic and symptomatic group of patients. This unicentric prospective observational study took place in University Hospital Brno between January 2016 and December 2019. A total of 264 patients met inclusion criteria (26% asymptomatic, 74% with reported symptoms). We did not find a statistically significant difference in clinical characteristics (menopausal status, parity, age, BMI, and serum level of CA 125) between groups. According to ultrasound examination, bleeding tumors were larger (19.5 vs. 12.7 mm, p <= 0.001). Definitive histology results indicated more frequent lymphovascular space invasion (p < 0.001), along with deep myometrial (p = 0.001) and cervical (p = 0.002) invasion. There was no difference in advanced stages of the tumor. We did not substantiate statistically significant difference in immunohistochemical profile (estrogen and progesterone receptors, L1 cell adhesion molecule, tumor protein p53), which is relevant for tumor recurrence risk and survival capacity. Our conclusions affirmed that bleeding occurs more often among patients with local tumor invasion into the myometrium and cervical stroma. Final International Federation of Gynecology and Obstetrics (FIGO) stage, histology, and immunohistochemical characteristics do not significantly affect symptom appearance.